Send Email

Working Hours

Mon-Fri 08:00AM - 06:00PM

Need Any Help?


Product Detail

  • Brigatinib
  • Brigatinib
  • Brigatinib
  • Brigatinib


  • CAS NO.1197953-54-0:
  • MF :C29H39ClN7O2P:
  • MW:584.1:
  • Reference standard:In-house:
  • Documentation:China DMF:
  • Inquiry

Product Description

Brigatinib is an orally administered inhibitor of receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) with potential antitumor activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutants. This leads to the inhibition of ALK kinase and EGFR kinase, disrupting their signaling pathways and ultimately inhibiting the growth of susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a range of tumors. EGFR is overexpressed in a variety of cancer cell types.

Hits: 【Print】